Search
Ropeginterferon alfa-2b
go.drugbank.com/drugs/DB15119ApprovedInvestigational[A242015, L39170] Ropeginterferon alfa-2b has shown efficacy in PV in _in vitro_ and _in vivo_ models and clinical trials. … Polycythemia vera (PV) is the most common Philadelphia chromosome-negative myeloproliferative neoplasm (MPN), characterized by increased hematocrit and platelet/leukocyte counts, an increased risk for
Products: BESREMi PenStreptococcus pneumoniae type 4 capsular polysaccharide antigen
go.drugbank.com/drugs/DB10322ApprovedInvestigationalIt is an active immunization for intramuscular or subcutaneous injection against pneumococcal disease such as pneumococcal pneumonia and pneumococcal bacteremia.
Mixtures: Prevnar 20, SYNFLORIX 0,5 ML IM ENJ. ICIN SUS.ICEREN KUL.HAZIR ENJEKTORSilver
go.drugbank.com/drugs/DB12965ApprovedInvestigationalSilver (Ag) is a chemical element that belongs in the family of transition metals in the periodic table. It has a high electrical conductivity, thermal conductivity, and reflectivity. … Having critical roles in various applications inducing chemical and industrial fields, silver compounds have also been used in the field of medicine for centuries due to their broad-spectrum biological
Mixtures: G SolProducts: G SOL SanitizingLevomefolic acid
go.drugbank.com/drugs/DB11256ApprovedSupplementation of levomefolic acid is desired over folic acid due to reduced potential for masking vitamin B12 deficiency symptoms. … Levomefolic acid (INN) is the metabolite of folic acid (Vitamin B9) and it is a predominant active form of folate found in foods and in the blood circulation, accounting for 98% of folates in human plasma
Synonyms: N-[4-[[[(6S)-2-Amino-3,4,5,6,7,8-hexahydro-5-methyl-4-oxo-6-pteridinyl]methyl]amino]benzoyl]-L-glutamic acidMixtures: PNV Tabs 20-1, EnlNorclozapine
go.drugbank.com/drugs/DB05766InvestigationalIt combines an atypical antipsychotic efficacy profile with the added potential benefit of enhanced cognition, thereby addressing one of the major challenges in treating schizophrenia today. … ACP-104, or N-desmethylclozapine, is the major metabolite of clozapine, and is being developed by ACADIA as a novel, stand-alone therapy for schizophrenia.
Synonyms: N-DesmethylclozapineNafcillin
go.drugbank.com/drugs/DB00607ApprovedInvestigationalIt may be used as a first-line therapy in Methicillin-Sensitive *Staphylococcus aureus* infections [A20360].
Nelistotug
go.drugbank.com/drugs/DB19334InvestigationalCell Carcinoma of the Head and Neck- GALAXIES H&N-202). … Nelistotug is under investigation in clinical trial NCT06062420 (A Platform Study of Novel Immunotherapy Combinations as First-line Treatment in Participants With PD-L1 Positive Recurrent/metastatic Squamous
Synonyms: CH1 K120, CH3 D12, L14 (CH1 K120 (219) (123-220), hi, Gamma1 heavy chain Homo sapiens (1-452) [VH(Homo sapiens IGHV1-69*01 (95.9%) -(IGHD)-IGHJ1*01 (90.9%) L123>T (117), CDR-IMGT [8.8.15](26-33.51-58.97-111)) (1-122) -Homo sapiens IGHG1*01 (100%), G1m17,1Dexmethylphenidate
go.drugbank.com/drugs/DB06701ApprovedInvestigationalDexmethylphenidate is the dextrorotary form of methylphenidate introduced in 2002[A177181]. It is a norepinephrine-dopamine reuptake inhibitor (NDRI) and thus a psychostimulant[A177193]. … The d-isomer is thought to have greater effect with fewer side effects than the l-isomer or the racemic mixture[A177181].
Synonyms: D-TMP, d-threo-methylphenidateStreptococcus pneumoniae type 18c capsular polysaccharide antigen
go.drugbank.com/drugs/DB10335ApprovedInvestigationalIt is an active immunization for intramuscular or subcutaneous injection against pneumococcal disease such as pneumococcal pneumonia and pneumococcal bacteremia.
Mixtures: Prevnar 20, SYNFLORIX 0,5 ML IM ENJ. ICIN SUS.ICEREN KUL.HAZIR ENJEKTORFlorquinitau (18F)
go.drugbank.com/drugs/DB19215Approved[L64052,L64053] It is the second fluorine-18 tau PET imaging agent approved in the United States, after flortaucipir (Tauvid), which was approved in 2020.[L64054,L14114] … [L64052] Florquinitau F 18, also known as MK-6240, was approved by the FDA on August 14, 2026 for PET of the brain in adults with cognitive impairment who are being evaluated for Alzheimer's disease